Source comparison
BPC-157 GHK-Cu for Scar Minimization: Protocol Comparison
The table below compares administration routes, optimal timing windows, and tissue-specific efficacy for BPC-157 and GHK-Cu in scar reduction protocols. Both peptides can be used concurrently. Their mechanisms do not overlap or antagonize. Primary Mechanism An
This comparison does not assign a generated winner or score.
- The table below compares administration routes, optimal timing windows, and tissue-specific efficacy for BPC-157 and GHK-Cu in scar reduction protocols. Both peptides can be used concurrently. Their mechanisms do not overlap or antagonize.
- Primary Mechanism
- Angiogenesis acceleration, granulation tissue formation
- TGF-β suppression, MMP upregulation, collagen remodeling
- Complementary. BPC-157 shortens inflammatory phase, GHK-Cu directs remodeling
- Use both for surgical scars and keloid-prone areas
- Optimal Timing
- Days 1–21 post-injury (proliferative phase)
- Days 7–180 post-injury (remodeling phase)
- Stagger initiation. BPC-157 early, GHK-Cu through maturation
- Begin BPC-157 within 72 hours, add GHK-Cu at suture removal
- Administration Route
- Subcutaneous injection near wound site
- Topical (liposomal or DMSO vehicle) or subcutaneous injection
- BPC-157 injected, GHK-Cu topical unless deep dermal scarring
- Injectable BPC-157 + topical GHK-Cu for most indications
- Dosage Range
- 250–500 mcg daily
- 3–5 mM topical twice daily; 1–2 mg injectable 3×/week
- No dosage interaction. Full doses of each
- Maintain standard monotherapy doses when combining
- Tissue Specificity
- High efficacy in tendon, ligament, muscle; moderate in dermis
- High efficacy in dermal tissue, low penetration to deep structures
- BPC-157 for deep tissue, GHK-Cu for superficial dermis
- Match peptide to injury depth
- Professional Assessment
- Most effective when initiated during active wound healing; minimal benefit on mature scars
- Effective on scars up to 18 months post-injury; requires penetration strategy for topical use
- Combined protocols show additive benefit in hypertrophic and keloid-prone healing
- Concurrent use justified for surgical incisions, burn scars, and high-tension closures